Table 1. Correlation analysis of DHRS2 downregulation with clinicopathologic characteristics of ESCC patients.
| Clinicopathologic characteristics | DHRS2 downregulation | P-value |
|---|---|---|
| Age (years) | 0.836 | |
| <60 | 29/92 (31.52%) | |
| >=60 | 28/93 (30.11%) | |
| Gender | 0.911 | |
| Male | 32/105 (30.48%) | |
| Female | 25/80 (31.25%) | |
| Tumor cell differetiation | 0.703 | |
| Well | 6/25 (24.00%) | |
| Moderate | 40/114 (35.09%) | |
| Poor | 11/46 (23.91%) | |
| Tumor invasion | <0.001 | |
| 0–1 | 10/74 (13.51%) | |
| 2 | 3/10 (30.00%) | |
| 3 | 44/101 (43.56%) | |
| Lymph node metastasis | <0.001 | |
| − | 30/131 (22.90%) | |
| + | 27/54 (50.00%) | |
| Staging | <0.001 | |
| 0, I | 9/74 (12.16%) | |
| II, III, IV | 48/111 (43.24%) |
Abbreviations: DHRS2, short-chain dehydrogenase/reductase family, member 2; ESCC, eesophageal squamous cell carcinoma. Bold values indicate statistically significant.